MX370218B - Forma solida de dosificacion que comprende nicotina con alteracion organoleptica reducida. - Google Patents

Forma solida de dosificacion que comprende nicotina con alteracion organoleptica reducida.

Info

Publication number
MX370218B
MX370218B MX2014008271A MX2014008271A MX370218B MX 370218 B MX370218 B MX 370218B MX 2014008271 A MX2014008271 A MX 2014008271A MX 2014008271 A MX2014008271 A MX 2014008271A MX 370218 B MX370218 B MX 370218B
Authority
MX
Mexico
Prior art keywords
dosage form
nicotine
disturbance
film coating
solid nicotine
Prior art date
Application number
MX2014008271A
Other languages
English (en)
Other versions
MX2014008271A (es
Inventor
Katarina Lindell
Kristina Thyresson
Andreas Hugerth
Fredrik Nicklasson
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of MX2014008271A publication Critical patent/MX2014008271A/es
Publication of MX370218B publication Critical patent/MX370218B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una forma farmacéutica sólida de dosificación para liberar nicotina en la cavidad bucal, que comprende un núcleo encapsulado por al menos un recubrimiento de película, en donde el núcleo comprende nicotina y en donde el recubrimiento de película comprende al menos un polímero formador de película y al menos un componente para reducir una o más sensaciones organolépticas desagradables, y en donde el al menos un recubrimiento de película está desprovisto de nicotina y desprovisto de regulador.
MX2014008271A 2012-01-05 2013-01-07 Forma solida de dosificacion que comprende nicotina con alteracion organoleptica reducida. MX370218B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1200017 2012-01-05
PCT/SE2013/050005 WO2013103318A1 (en) 2012-01-05 2013-01-07 Solid nicotine-comprising dosage form with reduced organoleptic disturbance

Publications (2)

Publication Number Publication Date
MX2014008271A MX2014008271A (es) 2014-10-06
MX370218B true MX370218B (es) 2019-12-05

Family

ID=48744083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008271A MX370218B (es) 2012-01-05 2013-01-07 Forma solida de dosificacion que comprende nicotina con alteracion organoleptica reducida.

Country Status (19)

Country Link
US (1) US20130177646A1 (es)
EP (1) EP2800557B1 (es)
JP (1) JP6169609B2 (es)
KR (1) KR102056041B1 (es)
CN (1) CN104053433A (es)
AR (1) AR089670A1 (es)
AU (1) AU2013206983B2 (es)
BR (1) BR112014016624A8 (es)
CA (1) CA2862497C (es)
DK (1) DK2800557T3 (es)
ES (1) ES2848534T3 (es)
HK (1) HK1201448A1 (es)
HU (1) HUE053063T2 (es)
MX (1) MX370218B (es)
NZ (1) NZ626672A (es)
PH (1) PH12014501446A1 (es)
PL (1) PL2800557T3 (es)
WO (1) WO2013103318A1 (es)
ZA (1) ZA201405745B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014157264A1 (ja) * 2013-03-27 2014-10-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 口腔内崩壊性フィルムコーティング錠
PT3003285T (pt) * 2013-06-03 2022-05-02 Mcneil Ab Forma de administração farmacêutica sólida para libertação de pelo menos dois princípios ativos farmacêuticos na cavidade oral
WO2015068058A1 (en) * 2013-11-06 2015-05-14 Rk Technology & Investments Pte. Ltd. Tobacco free 'niconuts'and the process thereof
KR20170003926A (ko) * 2014-04-08 2017-01-10 산사 코포레이션 (바베이도스) 인코포레이티드 니코틴 제형 및 이의 제조방법
CN104489916B (zh) * 2014-12-02 2016-06-01 云南中烟工业有限责任公司 红醋栗提取物在卷烟中的应用
US9585835B1 (en) 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
CN109562075A (zh) 2016-07-05 2019-04-02 葛兰素史克消费保健（美国）控股有限责任公司 包含快速释放外包衣的口服剂型
US10500155B2 (en) 2017-05-22 2019-12-10 Johnson & Johnson Consumer Inc. Lozenge dosage form having a disintegrative tablet portion and a candy glass shell portion
ES2890975T3 (es) * 2017-12-08 2022-01-25 Fertin Pharma As Comprimido de nicotina
AU2018378649B2 (en) * 2017-12-08 2021-06-03 Fertin Pharma A/S Solid oral nicotine formulation
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11672862B2 (en) 2019-12-09 2023-06-13 Nicoventures Trading Limited Oral products with reduced irritation
US11883527B2 (en) 2019-12-09 2024-01-30 Nicoventures Trading Limited Oral composition and method of manufacture
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
MX2022007013A (es) 2019-12-09 2022-09-07 Nicoventures Trading Ltd Producto oral que comprende un canabinoide.
US11889856B2 (en) 2019-12-09 2024-02-06 Nicoventures Trading Limited Oral foam composition
SE544672C2 (en) * 2020-05-07 2022-10-11 Liw Innovation Ab New compositions for oral or nasal use
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
US20220387328A1 (en) * 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy
US20230109240A1 (en) * 2021-09-30 2023-04-06 L'oreal Compositions and methods for styling hair
CN117256920A (zh) * 2023-09-27 2023-12-22 东莞市吉纯生物技术有限公司 一种固体雾化物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1219291A (en) * 1910-12-13 1917-03-13 Chester Earl Gray Process of manufacturing products from milk and cream.
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
JP3707798B2 (ja) * 1996-05-13 2005-10-19 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム 口内薬剤輸送系
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6583160B2 (en) * 1999-04-14 2003-06-24 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
JP4044709B2 (ja) * 1999-11-19 2008-02-06 信越化学工業株式会社 水系フィルムコーティング剤及び経口固形製剤
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
SE0102197D0 (sv) * 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
WO2003003957A1 (en) * 2001-07-06 2003-01-16 Lavipharm Laboratories Inc. Quick dissolving oral mucosal drug delivery device with moisture barrier coating
JP5089840B2 (ja) * 2001-09-25 2012-12-05 救急薬品工業株式会社 ニコチン含有フィルム製剤
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
SG108299A1 (en) * 2002-06-11 2005-01-28 Inst Data Storage Method and apparatus for forming periodic structures
ES2285233T3 (es) * 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US7022750B2 (en) * 2003-04-04 2006-04-04 Ppg Industries Ohio, Inc. Anti-fouling coating containing copper and graphite
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
TW200950821A (en) * 2008-05-21 2009-12-16 Novartis Ag Tablettable chewing gums
DK2296486T3 (en) * 2008-05-26 2015-07-13 Fertin Pharma As Film-coated compressed gum
NZ591710A (en) * 2008-10-14 2012-11-30 Mcneil Ab Controlled release oral dosage form comprising at least one portion that is rapidly disintegrating and at least one portion that is slowly disintegrating
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20110268809A1 (en) * 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions

Also Published As

Publication number Publication date
AU2013206983A1 (en) 2014-07-03
MX2014008271A (es) 2014-10-06
NZ626672A (en) 2016-11-25
AU2013206983B2 (en) 2017-10-05
CA2862497A1 (en) 2013-07-11
ZA201405745B (en) 2016-06-29
BR112014016624A2 (pt) 2017-06-13
BR112014016624A8 (pt) 2017-07-04
DK2800557T3 (da) 2021-02-15
CN104053433A (zh) 2014-09-17
HUE053063T2 (hu) 2021-06-28
JP6169609B2 (ja) 2017-07-26
WO2013103318A1 (en) 2013-07-11
PH12014501446B1 (en) 2014-10-08
ES2848534T3 (es) 2021-08-10
EP2800557A1 (en) 2014-11-12
CA2862497C (en) 2020-04-14
EP2800557A4 (en) 2015-09-09
HK1201448A1 (en) 2015-09-04
RU2623018C2 (ru) 2017-06-21
PL2800557T3 (pl) 2021-06-14
KR102056041B1 (ko) 2019-12-16
RU2014132174A (ru) 2016-02-27
US20130177646A1 (en) 2013-07-11
KR20140108728A (ko) 2014-09-12
PH12014501446A1 (en) 2014-10-08
JP2015503581A (ja) 2015-02-02
AR089670A1 (es) 2014-09-10
EP2800557B1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
PH12014501446A1 (en) Solid nicotine-comprising dosage form with reduced organoleptic disturbance
IL263175B (en) Microbiota restoration therapy (mrt) compounds and methods of manufacture
EP3065808A4 (en) Devices and methods for continuous drug delivery via the mouth
PH12016501006A1 (en) Dentifrice compositions comprising zinc oxide and zinc citrate
PH12016501033B1 (en) Oral care composition
WO2012110835A3 (en) Prussian blue based nanoparticle as multimodal imaging contrast material
EP2956126A4 (en) PHARMACEUTICAL COMPOSITION FORMING FILM FOR HEALING WOUNDS, AND PREPARATION METHOD THEREOF
EP2580624A4 (en) RESIN COMPOSITION SENSITIVE TO ACTINIC RAYS OR ACTINIC IRRADIATION, FILM SENSITIVE TO ACTINIC RADIATION OR IRRADIATION MANUFACTURED THEREFROM, AND METHOD OF FORMING A PATTERN USING THE COMPOSITION
MX357636B (es) Formas de dosificacion solidas que comprenden miel en el recubrimiento.
EP3013348A4 (en) A medicinal composition of amaranth extract origin having enriched nitrate content and a method of preparing the same
MY177265A (en) Wax encapsulated flavour delivery system for tobacco
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
WO2011104652A3 (en) Veterinary compositions
PH12016500970B1 (en) Wax encapsulated zeolite flavour delivery system for tobacco
EP3016708A4 (en) Metered dose inhaler and methods thereof
MY162550A (en) Taste-masked oral care compositions
HK1209371A1 (en) Oral and or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
EP3071350A4 (en) Coated casting cores and manufacture methods
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
EP2929786A4 (en) COMPOSITION WITH NATURAL POLYPHENOL COMPOUNDS AND COMPOSITION FOR ORAL ADMINISTRATION THEREWITH
PH12016500693B1 (en) Slow-release solid oral compositions
WO2015027160A3 (en) Allosteric modulators of the cannibinoid 1 receptor
EP3080246A4 (en) Compositions and methods for producing and administering brown adipocytes
WO2012156997A3 (en) Multi-particulate pharmaceutical composition

Legal Events

Date Code Title Description
FG Grant or registration